Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Merck (MRK) says it Capvaxive vaccine showed positive immune responses in a Phase 3 trial for adults at risk for pneumonia.

Focus on international early-stage and pre-commercial biotech & medtech opportunities ...

Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.

With the recent expansion of our research and manufacturing capabilities, it is the perfect time to bring additional expertise to our leadership team in the critical areas of commercialization, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.